Spruce Biosciences, Inc.
NASDAQ:SPRBBiotechnology
+$2.47 today
- Market cap
- $117.37M
- Beta
- 3.20
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$27.11
Volume 0.06M
Average 0.06M
SPRB EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Spruce Biosciences, Inc.NASDAQ: SPRB
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$11.34M, compared with -$14M a year earlier. Trailing-twelve-month EBITDA was -$36.2M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -$24.21M (+37.7%) for the fiscal year ending Dec 2026, a step up from the +26.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$11.34M+22.5% QoQ
- Last fiscal yearDec 2025
- -$38.86M+26.2% YoY
- LTMMar 2026
- -$36.2M+34.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +19.0% | — | — |
| 1 year | +26.2% | +37.7% | +11.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (38.86M) USD
- Year-over-year change
- +26.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (38.86M) | +26.2% |
| FY2024 | 2024-12-31 | (52.68M) | -11.2% |
| FY2023 | 2023-12-31 | (47.37M) | -3.7% |
| FY2022 | 2022-12-31 | (45.69M) | -9.1% |
| FY2021 | 2021-12-31 | (41.88M) | — |
EBITDA vs competitors
How SPRB compares with its peers on the latest reported figures
- SPRB's LTM Mar 2026 EBITDA of -$36.2M is the 8th highest of the 9 companies compared; the peer median is -$20.48M.
- Its year-over-year change of +34.4% is the 4th highest of 9, against a peer median of -4.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$715K | +96.9% | — | 1.9% | |
| LTM Mar 2026 | -$10.87M | -9.4% | — | 769.0% | |
| LTM Mar 2026 | -$15.84M | +57.4% | — | 48.4% | |
| LTM Mar 2026 | -$18.95M | -40.5% | — | — | |
| LTM Jun 2026 | -$22.02M | +66.8% | — | 104.8% | |
| LTM Mar 2026 | -$23.33M | -0.3% | — | 1017.5% | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | -$34.71M | -256.5% | — | — |
| LTM Mar 2026 | -$36.2M | +34.4% | — | — | |
| LTM Mar 2026 | -$62.08M | -482.8% | — | 18634.1% | |
| Peer median (excluding SPRB) | -$20.48M | -4.9% | — | 436.9% | |
Competitors are the stored peer set for SPRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 10.09M | 4.91M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 10.09M | 4.91M | 0 |
| Gross Margin | — | — | 100.0% | 100.0% | — |
| Research & Development | 30.7M | 35.2M | 49.43M | 46.42M | 19.52M |
| Selling, General & Admin | 11.37M | 12.09M | 12.65M | 14.64M | 16.99M |
| Operating Expenses | 42.07M | 47.28M | 62.08M | 61.06M | 36.51M |
| Depreciation & Amortization | 68K | 74K | 70K | 46K | 21K |
| EBITDA | (41.88M) | (45.69M) | (47.37M) | (52.68M) | (38.86M) |
| EBITDA Margin | — | — | -469.5% | -1072.8% | — |
| Operating Income | (42.07M) | (47.28M) | (51.99M) | (56.15M) | (36.51M) |
| Operating Margin | — | — | -515.3% | -1143.4% | — |
| Interest Income | 119K | 1.52M | 4.56M | 3.42M | 1.14M |
| Interest Expense | 345K | 420K | 483K | 307K | 90K |
| Other Income / Expenses | (226K) | 1.1M | 4.07M | 3.12M | (2.45M) |
| Income Before Tax | (42.29M) | (46.18M) | (47.92M) | (53.04M) | (38.97M) |
| Pre-Tax Margin | — | — | -475.0% | -1079.9% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (42.29M) | (46.18M) | (47.92M) | (53.04M) | (38.97M) |
| Net Margin | — | — | -475.0% | -1079.9% | — |
| EPS (Basic) | (68.25) | (72.00) | (93.00) | (96.75) | (50.83) |
| EPS (Diluted) | (68.25) | (72.00) | (93.00) | (96.75) | (50.83) |
| Weighted Avg Shares | 607.4K | 611.71K | 500.63K | 536.44K | 766.6K |
| Weighted Avg Shares (Diluted) | 607.4K | 611.71K | 500.63K | 536.44K | 766.6K |
Spruce Biosciences, Inc.
NASDAQ:SPRB
Intrinsic Alpha fair value
Locked
Current Price
$40.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.